Cargando…

Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach

In recent years, advances in knowledge of molecular mechanisms involved in asthma have changed uncontrolled severe asthma (USA) treatment, with the appearance of biological treatment. USA is a heterogeneous entity with different endotypes and phenotypes. Nowadays, the biological drugs approved with...

Descripción completa

Detalles Bibliográficos
Autores principales: López-Viña, Antolín, Díaz Campos, Rocío M., Trisan Alonso, Andrea, Melero Moreno, Carlos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701749/
https://www.ncbi.nlm.nih.gov/pubmed/36452259
http://dx.doi.org/10.3389/falgy.2022.1007593
_version_ 1784839605343748096
author López-Viña, Antolín
Díaz Campos, Rocío M.
Trisan Alonso, Andrea
Melero Moreno, Carlos
author_facet López-Viña, Antolín
Díaz Campos, Rocío M.
Trisan Alonso, Andrea
Melero Moreno, Carlos
author_sort López-Viña, Antolín
collection PubMed
description In recent years, advances in knowledge of molecular mechanisms involved in asthma have changed uncontrolled severe asthma (USA) treatment, with the appearance of biological treatment. USA is a heterogeneous entity with different endotypes and phenotypes. Nowadays, the biological drugs approved with asthma indication are omalizumab, mepolizumab, reslizumab, benralizumab and dupilumab. Tezepelumab is approved by the Food and Drug Administration (FDA) in the United States and, recently, by the European Medicines Agency (EMA). All these biological drugs have shown their efficacy in clinical trials, especially in reducing exacerbations, improving asthma control, quality of life, pulmonary function, and withdrawing systemic corticosteroids or at least reducing their daily dose, with some differences between them. Except for mepolizumab and reslizumab, biological drugs have different targets and thus different therapeutic indications should be expected; however, in some patients, more than one drug could be indicated, making the election more difficult. Because there are no direct comparisons between biological drugs, some biomarkers are used to choose between them, but they are not unbeatable. In this article, an algorithm to choose the first biological drug in a specific patient is proposed based on different study results and patient’ characteristics.
format Online
Article
Text
id pubmed-9701749
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-97017492022-11-29 Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach López-Viña, Antolín Díaz Campos, Rocío M. Trisan Alonso, Andrea Melero Moreno, Carlos Front Allergy Allergy In recent years, advances in knowledge of molecular mechanisms involved in asthma have changed uncontrolled severe asthma (USA) treatment, with the appearance of biological treatment. USA is a heterogeneous entity with different endotypes and phenotypes. Nowadays, the biological drugs approved with asthma indication are omalizumab, mepolizumab, reslizumab, benralizumab and dupilumab. Tezepelumab is approved by the Food and Drug Administration (FDA) in the United States and, recently, by the European Medicines Agency (EMA). All these biological drugs have shown their efficacy in clinical trials, especially in reducing exacerbations, improving asthma control, quality of life, pulmonary function, and withdrawing systemic corticosteroids or at least reducing their daily dose, with some differences between them. Except for mepolizumab and reslizumab, biological drugs have different targets and thus different therapeutic indications should be expected; however, in some patients, more than one drug could be indicated, making the election more difficult. Because there are no direct comparisons between biological drugs, some biomarkers are used to choose between them, but they are not unbeatable. In this article, an algorithm to choose the first biological drug in a specific patient is proposed based on different study results and patient’ characteristics. Frontiers Media S.A. 2022-11-14 /pmc/articles/PMC9701749/ /pubmed/36452259 http://dx.doi.org/10.3389/falgy.2022.1007593 Text en © 2022 López-Viña, Díaz Campos, Trisán Alonso and Melero Moreno. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) (https://creativecommons.org/licenses/by/4.0/) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Allergy
López-Viña, Antolín
Díaz Campos, Rocío M.
Trisan Alonso, Andrea
Melero Moreno, Carlos
Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach
title Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach
title_full Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach
title_fullStr Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach
title_full_unstemmed Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach
title_short Uncontrolled severe T2 asthma: Which biological to choose? A biomarker-based approach
title_sort uncontrolled severe t2 asthma: which biological to choose? a biomarker-based approach
topic Allergy
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701749/
https://www.ncbi.nlm.nih.gov/pubmed/36452259
http://dx.doi.org/10.3389/falgy.2022.1007593
work_keys_str_mv AT lopezvinaantolin uncontrolledseveret2asthmawhichbiologicaltochooseabiomarkerbasedapproach
AT diazcamposrociom uncontrolledseveret2asthmawhichbiologicaltochooseabiomarkerbasedapproach
AT trisanalonsoandrea uncontrolledseveret2asthmawhichbiologicaltochooseabiomarkerbasedapproach
AT meleromorenocarlos uncontrolledseveret2asthmawhichbiologicaltochooseabiomarkerbasedapproach